Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.2590

THU0633 TEMPERATURE SENSITIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

P. Mandl¹, F. Alasti¹, A. Kerschbaumer¹, R. Kaltenberger², T. Krennert², G.M. Supp¹, U. Landesmann¹, J.S. Smolen¹, D. Aletaha¹. ¹Department of Rheumatology, Medical University of Vienna; ²Central Institute for Meteorology and Geodynamics, Vienna, Austria

Background: Studies evaluating weather sensitivity among patients with rheumatoid arthritis (RA) have yielded conflicting results.

Objectives: To evaluate whether patients with RA exhibit sensitivity to outside temperature.

Methods: We assessed correlation between mean daily temperature and self-reported pain (by visual analogue scale), and patient's global assessment of disease activity (PGA). Assessments documented in the RA database of our department as well as the average temperature obtained from the Central Institute for Meteorology and Geodynamics, were matched on a daily basis for a period of 10 years between 2005 and 2015 and analyzed using generalized estimating equation (GEE) and a mixed model analysis (MM). Patients with <5 visits in the study period, or with <1 visit/quarter or with pain=0 in ≥3 consecutive visits and those living outside of the catchment area were excluded. Overlap between responsiveness of pain or PGA to temperature was calculated by Cohen's kappa.

Results: A total of 399 patients with RA (average disease duration at first visit: 6.0±7.6 years, average age: 57.7±13.9 years, 82% female, mean CDAI 19.7±11.5, 59.9% rheumatoid factor positive) were analyzed. Lower temperatures correlated significantly with higher pain levels (estimate: -0.07, p=0.021) in GEE, however the effect size was very small. When we performed MM with temperature as independent variable and VAS pain or PGA as dependent variable, the majority of patients showed no sensitivity to temperature, however 22% of patients were significantly sensitive to cold temperature with an estimate of -0.29 (p<0.0001) for pain and -0.21 (p=0.0005) for PGA (Figure 1). When we evaluated whether patients who demonstrate temperature-sensitivity to pain also exhibit temperature-sensitivity to PGA, we found an excellent overlap between the two patient groups (kappa: 0.81).

Figure 1. Mixed model analysis of influence of temperature on pain of patients demonstrating sensitivity to cold temperature

Conclusions: Our results indicate that a subgroup of patients with RA show significant sensitivity to cold temperature, and that these patients are characterized by higher pain and PGA levels at lower daily temperatures. These aspects may have to be taken into account in longitudinal analyses of disease activity of RA.

Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2017-eular.5134

THU0634 COMPARING PREFERENCES OF PATIENTS WITH RHEUMATIC DISEASES, OF RHEUMATOLOGISTS, NURSES AND PHARMACISTS TOWARD THE TREATMENT OF RHEUMATIC DISEASES WITH BIOLOGICAL AGENTS: RESULTS FROM THE CARA STUDY

P. Sarzi-Puttini¹, P.A. Cortesi^{2,3}, L. Sinigaglia⁴, C.M. Montecucco⁵, R. Giacomelli⁶, G. Lapadula⁷, I. Olivieri⁸, A. Giardino⁹, G. Dldoni¹⁰, L. Scalone^{2,3}, L.G. Mantovani^{3,11}, M. Mecchia¹⁰ on behalf of CARA Working group. ¹Rheumatology Unit, L. Sacco University Hospital, Milano; ²University of Milano-Bicocca, Monza; ³CHARTA Foundation; ⁴Rheumatology Unit, G. Pini Hospital, Italy, Milano; ⁵University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia; ⁶Rheumatology Unit School of Medicine, University of L'Aquila, L'Aquila; ⁷Rheumatology Unit, University of Bari, Bari; ⁸San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, and the Basilicata Ricerca Biomedica (BRB) Foundation, Potenza and Matera; ⁹MSD; ¹⁰MSD Italia, Roma; ¹¹University of Milano Biccoca, Monza, Italy

Background: The management of patients with rheumatologic diseases (RDs) involves a complex interaction between different parties such as patients,

physicians, pharmacists. The development of biologic therapies has created a more complex decision-making process to select the treatment option for patients. To optimize the appropriateness of the decisions, it is necessary to be informed and aware of the preferences of the interested parties.

Objectives: To estimate preferences of relevant treatment characteristics with biological agents valued by the different subjects involved in the management of patients with rheumatic diseases.

Methods: We involved patients with RDs, rheumatologists, nurses and pharmacists with experience in the treatment with/provision of biological drugs of these patients. Through a Discrete-Choice-Experiment, the participants valued 16 possible scenarios in which pairs of similarly effective treatments were described with 6 characteristics including 2–4 possible levels each: (1) frequency of administration; (2) mode and place of administration; (3) hospitality, service, efficiency and courtesy of health personnel; (4) frequency of reactions at the site of drug administration; (5) generalized undesired/allergic reactions; (6) additional cost: since the Italian NHS pays treatment costs, we included possible additional cost as monthly healthcare taxes for all the citizens, to make available the treatment to all target patients. relative importance of each characteristic was estimated through a random-effects conditional logistic regression model.

Results: 513 patients, 110 rheumatologists, 51 nurses and 46 pharmacists from 30 centres through Italy participated. Characteristics (3), (4) and (6) were the most important for every subgroup, while (1) was the least important for patients and rheumatologists, (2) the least important for the pharmacists, (2) and (5) the least important for the nurses. The four subgroups were consistent in preferences towards the specified levels of characteristics (1) and (3) to (6). However, as for characteristic (2), pharmacists preferred autonomous subcutaneous injection with syringe, nurses preferred assisted infusion at an infusional center close to patient's place, patients and rheumatologists preferred autonomous subcutaneous injection with pen.

Conclusions: Different subjects show different preferences for some treatment characteristics, which together with pure clinical aspects can play an important role in the choice and consequent success of treatments.

Disclosure of Interest: P. Sarzi-Puttini: None declared, P. Cortesi Grant/research support from: Gilead, L. Sinigaglia: None declared, C. Montecucco: None declared, R. Giacomelli Grant/research support from: MSD, G. Lapadula: None declared, I. Olivieri: None declared, A. Giardino Employee of: MSD Italia, G. Dldoni Employee of: MSD Italia, L. Scalone: None declared, L. Mantovani: None declared, M. Mecchia Employee of: MSD Italia

DOI: 10.1136/annrheumdis-2017-eular.4833

THU0635 PRECISE AND SIMPLE ALGORITHM TO IDENTIFY RA CASES IN ELECTRONIC MEDICAL RECORDS

R. Knevel^{1,2,3,4}, S. Raychaudhuri^{1,2,4}, K. Liao^{1,2}, T.W. Huizinga³. ¹Rheumatology, Brigham and Women's Hospital, Boston; ²Harvard Medical School, Cambridge, United States; ³Rheumatology, Leids Universitair Medisch Centrum, Leiden, Netherlands; ⁴Broad Institute, Cambridge, United States

Background: Electronic medical records (EMR) have emerged as a large-scale data collection option for observational studies. These huge data registries create new opportunities to study the rheumatologic phenotype and the real-life implications for these diseases. EMR usage poses new questions of quality management, such as how to reliably identify patients with the disease or phenotype of interest, as well as bioinformatic tools to handle the magnitude of data.

Thusfar, the algorithms used to identify cases are often not validated and overly simplify by using one financial code, or they are well-validated but require very specific information which hampers the applicability to other datasets.

Objectives: *Aim I:* Test the accuracy of the identification of patients with rheumatoid arthritis (RA) using the financial coding system.

Aim II: Develop a simple and precise algorithm to select patients with RA that is easy to implement at other centers.

Methods: *Aim I:* Out of the 16,183 Rheumatology patients in the Leiden out-patient EMR system 400 charts were randomly selected and reviewed for the rheumatologic diagnosis. Next, the charts were reviewed for 200 randomly selected patients that were labeled as RA in the financial system.

Aim II: To enable generalizability, only codified data that was obtained at regular outpatient clinic visits was used. Lasso regression was applied to identify the most discriminative variables.

Results: *Aim I:* Since 2008, 16,183 patients were enrolled in the EMR system of the Leiden rheumatology outpatient clinic. 2,845 of these patients were classified as having RA in the financial system. 63/400 (16.3%) of the reviewed charts concerned patients with RA. The majority (n=57) were registered as having RA in the financial system. Still, 33% of the patients with the financial code RA did not have RA.

Aim II: Using Least Absolute Shrinkage and Selection Operator (LASSO) regression anti CCP, MTX prescription and number of visits were identified as the most discriminative variables. Combining these with the presence of the financial code for RA improved the algorithm from an accuracy of 67% to 90%.

Conclusions: The vast majority of patients that are classified as having RA are registered as such in the financial system. However, a substantial number of patients are registered as RA in the financial system are not classified as RA in clinical charts. Using widely available data on anti-CCP status, MTX prescription

and visit count improved the selection of RA patients from a 67% to 90% accuracy. The combination of these variables provides a widely applicable algorithm, as they are broadly registered in Rheumatology clinics.

Subsequent replications are ongoing.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6464

THU0636 INFLUENZA AND MENINGOCOCCAL C VACCINATIONS IN A COHORT OF PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: ADHERENCE, SAFETY AND IMMUNOGENICITY

R. Vagelli, C. Tani, L. Maggi, E. Elefante, A. Parma, E. Cioffi, S. Talarico, C. Baldini, C. Stagnaro, A. Delle Sedie, S. Vagnani, M. Mosca. *Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy*

Background: The EULAR recommendations for vaccination in adult patients with autoimmune rheumatic diseases strongly recommend inactivated influenza vaccination. Insufficient data are available about safety and efficacy of meningococcal C vaccination. In 2015–2016, after an increased incidence of meningitis C infections in our country, the health care system has promoted a free meningococcal vaccination campaign.

Objectives: To evaluate the adherence to the EULAR recommendations for influenza vaccination and to the meningococcal C vaccination campaign in a cohort of patients with autoimmune rheumatic diseases and to assess their safety. The efficacy in term of immune response to meningococcal C vaccination has been also evaluated.

Methods: Consecutive in- and out-patients seen at our unit from February to December 2016 were enrolled in the study. Using a questionnaire created *ad hoc* the following data were collected: the percentage of patients who underwent influenza and/or meningococcal C vaccinations in the previous 12 months, the occurrence of adverse events and of disease flares after vaccinations, according with the report from the patients and with the rheumatologist clinical evaluation. Seroconversion rates in patients and healthy controls were assessed using ELISA kits for human anti-meningococcal ACWY IgG antibodies. Antibody titres were expressed in U/ml and according with kit reference value were classified in absent, low, medium and high titre.

Results: 286 patients (91% female) (143 SLE, 68 RA, 60 Scleroderma, 11 Sjögren Syndrome, 3 Behcet disease and 1 Dermatomyositis) were included in the analysis. The mean age at evaluation was 52.9±16.1 years, mean disease duration was 15.3±10 years. The 53.1% of patients was taking steroids, at an average dose of 4.2 mg of 6-metilprednisolone/day. 134/286 (46.9%) patients were on immunosuppressive therapies, of which 49/134 (36.6%) on biologic agents. The 19.9% (57/286) of patients underwent influenza vaccinations and the 13.3% (38/286) meningococcal C vaccination. 8 patients underwent both vaccinations. No disease flares were observed after vaccination; seven patients reported non-specific adverse events after influenza (fever, discomfort, nausea, arthralgia) and 2 patients after meningococcal C vaccination (fever, rash at the injection site, discomfort). Seroconversion after meningococcal vaccination was analysed in 27 patients and 9 healthy subjects, no statistically significant differences in terms of antibody response to meningococcal vaccination were observed between these two groups. Treatment (steroids and immunosuppressive drugs) did not influence antibody titres.

Conclusions: These data highlight the poor adherence to international recommendations on influenza vaccination in patients with autoimmune rheumatic disease at our Unit. The adherence to the meningococcal C vaccination campaign conducted in our country in 2015–2016 was also low. Our data confirm the safety of these vaccination and show that the immune response elicited by meningococcal C vaccination is comparable to healthy controls and is not influenced by therapy.

References:

[1] van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Annals of the rheumatic diseases* 2011; 70(3): 414–22.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6123

THU0637 PATIENT'S AND RHEUMATOLOGIST'S PERSPECTIVES ON THE FOLLOW-UP INTERVAL AS A TOOL FOR OPTIMIZED OUTPATIENT TREATMENT

S. Hermann, S. Fügner, E. Wiebe, T. Alexander, G.R. Burmester, F. Buttgerit. *Dept. of Rheumatology, Charité, Berlin, Germany*

Background: Scientific progress and better disease awareness constantly lead to increasing patient numbers in rheumatology which requires optimization of patient care.

Objectives: The aim of this study was to evaluate and to optimize the procedures of patient care in an university-based outpatient rheumatology setting in Berlin, Germany.

Methods: One hundred patients with rheumatoid arthritis (80 women, 20 men, mean age 61.2 years, mean disease duration 12.9 years) were independently assessed both by a rheumatologist and via patient-reported self-assessment questionnaires. Current follow-up interval (usually 3 months), patient's perspective

on follow-up intervals, signs of disease activity as well as individual patient concerns were recorded. Satisfaction with follow-up intervals was grouped into three categories: too early, just right/optimal, too late.

Results: Based on the physicians perspective, 46 patients presented at the optimal time point, 51 too early, and three too late. The patients reported the category "just right" in 82 cases, too early follow-up in 10 cases and too late in 8 cases. Of note, 51% (42 individuals) of all patients with self-reported satisfactory follow-up interval were judged to visit the out-patient department too early by the expert rheumatologist. When taking into account the follow-up interval and optimal satisfactory levels, 62% of patients were concluded to visit the department too early in those revisited after 3–4 months (n=65), and in 12% of those who were seen again after 5–6 months (n=17). 82% of patients in the latter group were judged to revisit just right by the physician.

Conclusions: There was a high proportion of overlap in the views on the satisfaction with follow-up intervals between physicians and patients. Especially in patients who were seen every 3–4 months, a high proportion was deemed to could have come later to the out-patient care unit from a purely medical point of view. Here we see a way to stretch the interval to 5–6 months without risking a long-term deterioration in patient care. However, this measure should be flanked by patient education and good collaboration with the general practitioners.

Acknowledgements: We thank AbbVie for financial support in the development of measures to optimize out-patient management in patients with rheumatoid arthritis. The sponsor did not influence the scientific results.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4748

THU0638 PREVALENCE AND DIRECT HEALTHCARE COSTS OF UPPER GASTROINTESTINAL (UGI) ADVERSE EVENTS IN ASIAN RHEUMATIC PATIENTS ON LONG-TERM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

S.L. Pok¹, F.H. Shabaruddin², J.Y. Teng², M. Dahlui³, C.T. Ng¹, S. Sockalingam¹, M.S. Said⁴, A. Rosman⁵, I.S. Lau⁵, L. Mohd Isa⁶, H. Hussain⁶, S. Mahadeva². ¹Dept. of Rheumatology; ²Dept. of Medicine; ³Dept. of Social & Preventive Medicine, University of Malaya; ⁴Dept. of Rheumatology, National University of Malaysia, Kuala Lumpur; ⁵Dept. of Rheumatology, Selayang Hospital, Selangor; ⁶Dept. of Rheumatology, Putrajaya Hospital, Kuala Lumpur, Malaysia

Background: NSAIDs are frequently used in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). NSAID-induced UGI adverse events are well described in the Western population but data is lacking in Asian patients.

Objectives: To describe the prevalence and direct healthcare costs of NSAID-induced UGI adverse events in a large cohort of RA and OA patients in Malaysia.

Methods: A retrospective cohort study of RA and/or OA patients who received long-term NSAIDs (minimum 4 weeks prescription of any NSAID) between 2010 and 2013 was conducted in 4 large tertiary care centres with rheumatology units in Malaysia. Electronic clinical records and pharmacy prescriptions were reviewed. Resource use data was collected in patients who developed UGI adverse events within the 24 months follow up period. Unit costs were estimated by combining top down (general overheads for hospital services) and bottom up (activity-based costing for clinic visits, hospitalisation, diagnostic investigations, medications) approaches.

Results: 634 patients were included in the final analysis with mean age 53.4±12.5 years, 90% female, diagnosis of RA in 60%, OA in 10% and both RA and OA in 30%. 45% and 8% of patients were on concomitant prednisone and aspirin respectively. 89% of patients had no previous upper GI disease. 59% and 41% of patients were grouped under non-selective and COX-2 inhibitor respectively. 84 (13.2%) patients developed UGI adverse events (Figure 1), consisting of 78 (12.3%) patients with dyspepsia, 5 (0.79%) with peptic ulcer disease (PUD) and 1 (0.16%) with upper GI bleeding (UGIB). The total direct cost was RM37,352 (USD 11,419) with a mean cost of RM447±535 (USD 137±163) per patient (Table 1). The largest cost components were pharmacotherapy (34%), oesophagoduodenoscopies (OGD) (23%) and outpatient visits (18%). The mean cost of dyspepsia was RM409±513 (USD 125±157) per patient. The mean cost of PUD and UGIB was approximately double (RM806±579) (USD 246±177) and quadruple (RM1,602) (USD 490) of dyspepsia respectively.

Healthcare resource	Mean cost per patient in RM (USD)			
	Dyspepsia (n=78)	PUD (n=5)	UGIB (n=1)	All patients with UGI adverse events (n=84)
Outpatient visits	77 (23)	146 (45)	146 (45)	82 (25)
Emergency Dept visits	28 (9)	0	146 (45)	28 (9)
Inpatient stay	46 (14)	136 (41)	679 (207)	59 (18)
OGD	85 (26)	253 (77)	211 (65)	103 (32)
Blood tests	4 (1)	32 (10)	57 (17)	6 (2)
Radiology	8 (3)	0	0	8 (3)
Blood transfusion	4 (1)	56 (17)	280 (86)	10 (3)
Pharmacotherapy	150 (46)	183 (56)	84 (26)	151 (46)
Mean cost per patient in RM ±SD (USD)	409 ±513 (125±157)	806±579 (246±177)	1602 (490)	447±535 (137±163)

Conclusions: The low prevalence of UGI adverse events in Malaysian rheuma-